AXIOS August 15, 2024
Alison Snyder

Negotiators from around the world are meeting in Montreal this week to hammer out how to divide the billions of dollars and other benefits derived from using genetic sequences to make new drugs, cosmetics and agricultural products.

Why it matters: Without a system for sharing the benefits, countries don’t have to be compensated by companies and can restrict access to genetic data and create obstacles to scientific research.

  • “It puts a whole lot of sand in the machine,” says Pierre du Plessis, a technical adviser to an African group of negotiators.
  • “It’s in everyone’s interest to put in place an agreed system for not unnecessarily restricting access to data.”

The dilemma for countries that take a hard line...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Conferences / Podcast, Govt Agencies, Pharma / Biotech, Precision Medicine, Trends
Bringing genomics closer to patients: 3 takeaways from Henry Ford Health
Oncologist talks personalized medicine for pancreatic cancer
AI offers a step above genomic solutions
How Mayo Clinic is using real-world data to advance precision medicine
Aignostics Secures $34 Million Series B to Enhance Precision Medicine with AI

Share This Article